Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419313 | 0.93 | MEN1 (0.49) | MEN1KMT2AABCG2CCR2ALDH1A1 | |
| SCHEMBL4968428 | 0.93 | MEN1 (0.44) | MEN1KMT2AABCG2CCR2ALDH1A1 | |
| SCHEMBL2423280 | 0.91 | KMT2A (0.50) | MEN1KMT2AABCG2ALDH1A1LMNA | |
| SCHEMBL2425516 | 0.90 | MEN1 (0.54) | MEN1KMT2ACCR2ALDH1A1LMNA | |
| SCHEMBL2423026 | 0.89 | MAPK9 (0.51) | MEN1KMT2ACCR2ALDH1A1LMNA | |
| SCHEMBL2428331 | 0.89 | KMT2A (0.51) | MEN1KMT2ACCR2ALDH1A1LMNA | |
| SCHEMBL2419389 | 0.89 | KMT2A (0.50) | MEN1KMT2ACCR2ALDH1A1LMNA | |
| SCHEMBL2421919 | 0.89 | MEN1 (0.47) | MEN1KMT2ACCR2ALDH1A1LMNA | |
| SCHEMBL4196453 | 0.88 | MEN1 (0.41) | MEN1KMT2AABCG2CCR2ALDH1A1 | |
| SCHEMBL2422778 | 0.88 | MEN1 (0.51) | MEN1KMT2AABCG2CCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | claimed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1663193-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-07 | — | — | EP | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| WO-2005025558-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | MEN1 4590/4885KMT2A 2086/4885ABCG2 4585/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | MEN1 3205/4885KMT2A 2101/4885ABCG2 575/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MEN1 1582/4885KMT2A 3013/4885ABCG2 4508/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MEN1 3898/4885KMT2A 847/4885ABCG2 4771/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | MEN1 4390/4885KMT2A 1484/4885ABCG2 4798/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MEN1 3898/4885KMT2A 847/4885ABCG2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.